Experimental infection of animals via inhalation containing pathogenic agents is essential to 18 understanding the natural history and pathogenesis of infectious disease as well as evaluation of 19 potential medical countermeasures. We evaluated whether the Aeroneb, a vibrating mesh 20 nebulizer, would serve as an alternative to the Collison, the 'gold standard' for generating 21 infectious bioaerosols. While the Collison possesses desirable properties that have contributed to 22 its longevity in infectious disease aerobiology, concerns have lingered about the volume and 23 concentration of agent required to cause disease and the damage that jet nebulization causes to 24 the agent. For viruses, the ratio of aerosol concentration to nebulizer concentration (spray factor, 25 SF), the Aeroneb was superior to the Collison for four different viruses in a nonhuman primate 26 head-only exposure chamber. Aerosol concentration of influenza was higher relative to 27 fluorescein for the Aeroneb compared to the Collison, suggesting that the Aeroneb was less 28 harsh to viral pathogens than the Collison when generating aerosols. The Aeroneb did not 29 improve the aerosol SF for a vegetative bacterium, Francisella tularensis. Environmental 30 parameters collected during the aerosols indicated that the Aeroneb generated a higher relative 31 humidity in exposure chambers while not affecting other environmental parameters. Aerosol 32 mass median aerodynamic diameter was generally larger and more disperse for aerosols 33 generated by the Aeroneb than what is seen with the Collison but ≥80% were within the range 34 that would reach the lower respiratory tract and alveolar regions. These data suggest that for viral 35 pathogens, the Aeroneb is a suitable alternative to the Collison 3-jet nebulizer. 36 Importance 37 The threat of aerosolization is often not the natural method of transmission. While selection of 38 an appropriate animal model is vital for these types of experiments, other confounding factors 39 can be controlled through a thorough understanding of experimental design and the effects that 40 different parameters can have on disease outcome. Route of administration, particle size, and 41 dose are all factors which can affect disease progression and need to be controlled. Aerosol 42 research methods and equipment need to be well characterized to optimize the development of 43 animal models for bioterrorism agents.
Introduction
Experimental infection of animals with aerosolized pathogens to study pathogenesis or 48 evaluate medical countermeasures remains a complicated procedure that requires expert training 49 and highly sophisticated equipment. Environmental and situational factors can affect the 50 survival, dose, site of deposition, and virulence of pathogenic agents (1) (2) (3) (4) . For example, studies 51 have shown that relative humidity inside the chamber can alter aerosolization of bacteria and 52 viruses (3, (5) (6) (7) . Particle size can affect where a pathogen lands in the respiratory tract, which can 53 have dramatic effects on pathogenesis and virulence (1, 2, 4, 8, 9) . Therefore, to achieve 54 reproducible dosing between experiments, one must fully characterize and validate all 55 parameters of an aerosol exposure. 56 The Collison 3-jet nebulizer is a commonly employed aerosol generator in infectious 57 disease aerobiology research (Fig. 1A) . The nebulizer utilizes Bernoulli's principle to shear a 58 liquid suspension into aerosolized particles, which impact against a hard surface (the interior of 59 the jar) to further break apart particles (10). A primary reason for the appeal of the Collison 60 nebulizer is that it generates high concentrations of particles that are relatively monodisperse 61 with a mass median aerodynamic diameter between 1-2 µm (11). This particle size can reach the 62 alveolar regions of the lung. However, some studies suggest the shear forces, impaction, and 63 recirculation of the infectious sample can damage organisms, potentially reducing pathogen 64 viability or infectivity (12, 13) . Damaged bacteria or viruses may also stimulate immune
Results

80
Aerosolization of viruses 81 Experimental aerosolization of pathogenic agents is commonly evaluated by 82 determination of the spray factor (SF), which is calculated as the ratio of the aerosol 83 concentration to the starting concentration. This allows one to compare between different 84 aerosols to evaluate the impact of aerosol generators, sampling devices, and environmental 85 parameters. A less commonly used alternative is aerosol efficiency (AE) that compares the 86 amount of agent aerosolized to what is recovered from aerosol sampling devices. Prior to 87 comparing nebulizers, we first sought to determine whether there was a difference in aerosol 88 performance of H3N2 and H1N1 influenza viruses in the ferret whole-body (FWB) and rodent 89 whole-body (RWB) chambers with the Collison nebulizer ( Figure 2 ). No significant differences 90 were seen between the SF of H1N1 and H3N2, regardless of the chamber used. Influenza spray 91 factors (SFs) were slightly higher in the RWB compared to the FWB but this difference was also 92 not statistically significant. The H1N1 data included aerosols with A/Ca/4/09 or A/PR/8/34; no 93 significant differences existed between the two isolates based on a two-sided Mann-Whitney test 94 (p =0.0901). In other experiments using other chambers and nebulizers, no differences in SF 95 were seen based on the choice of influenza subtype, strain, or method of propagation (eggs or 96 cell culture); the results in Table 1 and Figure 3 show combined results for all influenza viruses.
97
Comparison of aerosol performance of influenza strains between the Collison and 98
Aeroneb was assessed in the rodent nose-only tower (NOT), the FWB chamber, and the NHP 99 HO chamber. In the NOT, the SF for influenza was higher with the Collison and this difference 100 was significant (p = 0.0145) (Table 1, Figure 3A ). The range of influenza SF generated by the 101 Aeroneb in the NOT was also substantially broader than was seen with other nebulizer/chamber combinations (coefficient of variation = 2.09). Fluorescein was added as a control to measure 103 impact of the two nebulizers on pathogen viability. For both the Collison and Aeroneb in the 104 NOT, there was little or no loss when comparing influenza SF to fluorescein SF. In contrast, in 105 both the FWB and NHP HO chambers the Aeroneb outperformed the Collison as measured by 106 SF and AE (p<0.0001) (Table 1) . Further, there was a significant decrease in SF between the 107 fluorescein salt and influenza with the Collison in both the FWB and NHP HO chambers 108 (p<0.0001 for both) ( Figure 3B -C). This drop was not seen with the Aeroneb, suggesting there is 109 considerable loss of viable influenza in aerosols generated by Collison but not the Aeroneb in 110 these chambers.
111
To evaluate whether these results were specific to influenza viruses, we also generated 112 aerosols of RVFV into a RWB chamber and compared results obtained with the Aeroneb to prior 113 data obtained with the Collison. As shown in Figure 4A , the Aeroneb did generate a higher SF of 114 RVFV and the improvement was statistically significant (p<0.0001). For the encephalitic 115 alphaviruses, the Aeroneb was used to generate aerosols in an NHP HO chamber ( Figure 4B ).
116
For all three viruses, using the Aeroneb generated a SF that was a ½-1 log 10 improvement in SF 117 over similar results obtained previously with the Collison (D.S. Reed, personal observation), 118 however those results with the Collison were obtained with different virus isolates with some 119 differences in viral plaque assays and media so the results are not directly comparable.
120
Aerosolization of vegetative gram-negative bacteria 121 After demonstrating the dramatic improvement in SF for viral pathogens with the 122 Aeroneb, we sought to determine whether similar improvements would be seen with a vegetative 123 bacterium. We had previously shown no difference in SF between attenuated (LVS, the live 124 vaccine strain) and virulent (SCHU S4) strains of F. tularensis (Faith et al, 2012) . In those studies, we also found that the broth media used to propagate F. tularensis greatly impacted SF, 126 as did the relative humidity in the chamber. Aerosol performance of Brain-Heart Infusion (BHI)-127 grown LVS with the Aeroneb and Collison was assessed in the NOT and the RWB chambers 128 without supplemental humidification. In the NOT, the Collison generated a better SF and higher 129 AE for LVS than did the Aeroneb; this difference was significant (p< 0.0001) (Table 2, Figure   130 5). In contrast, in the RWB chamber, the Aeroneb had a slightly better SF than the Collison 131 which also was significant (p=0.0004). AE was also higher for the Aeroneb than the Collison in 132 the RWB. When comparing LVS SF to fluorescein SF in the NOT, we saw a significant, 2 to 3 133 log 10 decrease in the SF of LVS with both the Collison and the Aeroneb (p=0.0079, 0.0006, 134 respectively) ( Figure 5A ). An even more substantial decrease in the LVS SF compared to the 135 fluorescein SF was seen in the RWB chamber for both nebulizers (p<0.0001 for both) ( Figure   136 5B). This would suggest both nebulizers cause considerable loss of viable LVS although the 137 impact is less in the NOT. This is likely due to the high relative humidity (RH) achieved in the 138 NOT. The higher RH generated by the Aeroneb in the RWB could also explain the superior LVS 139 SF obtained with the Aeroneb in that chamber, as we have previously seen that raising RH above 140 60% improves LVS SF substantially (3). The Collison has been shown to generate a small (1-2 µm MMAD) particle that is 143 relatively monodisperse. These particles would reach the lower respiratory tract, including the 144 alveolar regions. The information from the manufacturer of the Aeroneb indicates it would 145 generate a somewhat larger particle (average 3.1 µm) which should also reach the alveolar 146 regions. Using an APS 3321, we evaluated particle sizes generated by the Collison and Aeroneb 147 in the different chambers. Initially, we used small (400 or 900 nm) microspheres, however, the 148 Aeroneb was not able to generate good, consistent aerosols with these microspheres. We believe 149 that this difficulty was a result of the microspheres clumping and not being able to readily pass 150 through the vibrating mesh, however, mild sonication did not measurably improve the results 151 (data not shown). If larger particles cannot readily pass through the vibrating mesh, this may 152 contribute to the lower SF obtained with LVS with the Aeroneb. For this reason, we used 153 fluorescein instead of microspheres to measure particle size. The results are shown in Table 3 . 154 Particle sizes obtained for the Collison were larger than expected, which we believe may be due 155 to higher surface tension in the aerosolized particles caused by the fluorescein salt. What table 3 156 does show though is that except for the NOT, the Aeroneb consistently generated larger particles 157 than the Collison and with a broader distribution (as measured by GSD) in all of the chambers 158 tested. The Aeroneb also generated a higher humidity in each chamber tested except for the 159 NOT, which would at least partly explain the differences in particle size seen. Even with the 160 larger particle sizes obtained with the Aeroneb using fluorescein, between 70-80% of the 161 particles measured were ≤5 µm MMAD. The only nebulizer/chamber combination to achieve 162 less than 70% was the Collison in the NOT, which only had 55.97% of particles ≤5 µm. This disease aerobiology studies because of its ease of use and relatively monodisperse particle size 173 that can reach the deep lung of rodents, ferrets, rabbits and nonhuman primates. However, the 174 method by which aerosols are generated by the Collison have been considered 'harsh' and could 175 damage microorganisms, impacting the dose required to cause infection/disease and the host 176 response to infection (12). The Collison also requires a relatively high volume of challenge 177 material (10 ml), which can be difficult to generate depending on the agent and nebulizer 178 concentration needed to achieve a desired challenge dose. These deficiencies can be a substantial 179 impediment to aerosol studies, particularly for pathogens that require a high challenge dose to 180 achieve infection/disease (e.g., alphaviruses in macaques). Alternative nebulizers that generate 181 small particles that would penetrate to the deep lung (≤5 µm), are less harsh on the 182 microorganism being aerosolized, and require less challenge material to achieve comparable or 183 higher doses would be desirable.
184
In agreement with what we have reported previously for F. tularensis and RVFV, the 185 choice of exposure chamber impacts aerosol performance with smaller chambers (by total 186 volume) typically producing a better SF than a larger chamber. The data we report here also 187 demonstrate that while the choice of nebulizer does affect SF, the impact is dependent upon the Medium, BSA, penicillin/streptomycin, 2% agarose). Plates were incubated at 37°C/5% CO 2 for 289 up to 5 days, depending on virus. Cells were fixed with 37% formaldehyde, agar plugs were 290 removed, and cells were stained with a 0.1% crystal violet stain to visualize plaques. Wells with 291 15 to 100 plaques were counted for titer calculations. H5N1 plaque assays were performed in the 292 same manner as seasonal influenza plaque assays with the following changes: following the 293 addition of inoculum, the plates were incubated at 4°C for 10 minutes, then incubated at 294 37°C/5% CO2 for 50 minutes; a 0.9% nutrient overlay was used instead of a 1.0% nutrient 295 overlay. added to each AGI. For RVFV aerosols, glycerol was also added. For VEEV, WEEV, and EEEV 317 aerosols, 1% FCS was also added to the culture media. Aerosol concentration was determined as 318 previously described (3, 5) .
319
Aerosol Performance: Aerosol performance between nebulizers was compared using SF and 320 aerosol efficiency (AE). SF was determined as previously described (3, 5) , the ratio of the 321 aerosol concentration (determined from the AGI) to the starting concentration in the aerosol 322 generator. AE is the ratio of the aerosol concentration to the theoretical maximum aerosol 323 concentration as previously described (18). Aerosol particle size as measured by mass median aerodynamic diameter (MMAD) and geometric square deviation (GSD) using an aerodynamic 325 particle sizer (APS) model #3321 (TSI, Shoreview, MN).
326
Fluorescein: Fluorescein salt (Sigma) was added to some aerosol experiments to be used as an 327 indicator of maximum SF given natural loss. Fluorescein salt was dissolved at a concentration of 328 0.1mg in 1ml of ddH2O prior to addition to nebulizer contents. Initial studies were conducted 329 (data not shown) to verify that addition of fluorescein did not alter pathogen viability or 330 quantitation in culture, whether by plating on agar (F. tularensis) or TCID 50 /plaque assay 331 (influenza). 
